GLP-1竞争新动向:礼来后来居上?

健识局
Yesterday

就在替尔泊肽与司美格鲁肽减肥药在市场缠斗之际,礼来再放“大招”。4月17日,礼来公布在研小分子口服GLP-1受体激动剂Orforglipron积极的Ⅲ期临床试验结果:在最高剂量下,每日一次的治疗中实现了平均减重7.3kg(7.9%),已达到主要终点。这意味着礼来的首款口服减肥药研发获得初步成功,全球两大GLP-1生产企业都要开始进入口服药的竞争中。当天礼来美股盘中一度涨近17%,收盘涨14.30%...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10